Opinion

Video

CIBMTR Registry and CARTITUDE-2: Trial of Cilta-Cel in Patients with MM

Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).

This is a video synopsis/summary of an OncLive® Post-Conference Perspectiveinvolving Rafat Abonour, MD, and Noopur Raje, MD.

Abonour and Raje discuss additional B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T-cell therapy data in relapsed/refractory multiple myeloma presented at the 2023 American Society of Hematology Annual Meeting and Exposition.

Abonour reviews results from a large real-world data set of patients treated with idecabtagene vicleucel (ide-cel) from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Despite high-risk features and comorbidities that would have excluded most patients from clinical trials, response rates were consistent with those in KarMMa and KarMMa-3 trials. Ide-cel demonstrates reproducibility across phase 3 and real-world data.

Pivoting to earlier lines of therapy, Raje highlights findings from the CARTITUDE-2 trial evaluating cilta-cel in patients after 1 to 3 prior lines of therapy. Deep responses were observed, with complete remission of 90% in both cohorts. However, some concerning neurotoxicity signals emerged, including delayed parkinsonism in some patients. This will be important to monitor as CAR T-cell therapy moves earlier into the treatment paradigm.

In conclusion, Abonour and Raje say they are encouraged by the latest BCMA CAR T-cell data but recognize the need to closely track safety, especially with earlier use.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Jill Corre, PharmD, PhD